Cover Image
市場調查報告書

H. Lundbeck A/S:開發中產品分析

H. Lundbeck A/S - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 192615
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
H. Lundbeck A/S:開發中產品分析 H. Lundbeck A/S - Product Pipeline Review - 2016
出版日期: 2016年03月22日 內容資訊: 英文 59 Pages
簡介

H. Lundbeck A/S是從事研究、開發、製造、銷售治療憂鬱症、精神分裂症、帕金森氏症、老年癡呆症、亨丁頓舞蹈症、癲癇、失眠症等中樞神經系統(CNS)相關疾病醫藥品的製藥公司。

本報告提供H. Lundbeck A/S所開發治療用平台產品的開發狀況調查分析,提供研究·開發概要,開發中產品的概要,實驗各階段產品概要,藥物簡介,開發平台分析,企業資料等,為您概述為以下內容。

目錄

H. Lundbeck A/S概要

H. Lundbeck A/S - 研究·開發概要

  • 主要治療領域

H. Lundbeck A/S - 開發平台檢驗

  • 開發中產品:各開發階段
  • 開發中產品 - 單獨療法
  • 開發中產品 - 聯盟產品
  • 開發中產品 - 轉出授權產品

H. Lundbeck A/S - 開發中產品的概要

  • 開發中產品 - 後期階段的開發中產品
  • 開發中產品 - 臨床實驗階段的開發中產品
  • 開發中產品 - 初期階段的開發中產品

H. Lundbeck A/S - 藥物簡介

  • carbamazepine
  • vortioxetine hydrobromide
  • desmoteplase
  • LuAE-58054
  • LuAF-11167
  • tedatioxetine
  • KW-6356
  • LUAF-20513
  • LUAF-64280
  • PDE 10A 抑制劑
  • 阻礙LRRK-2的小分子(帕金森氏症)

H. Lundbeck A/S - 開發平台分析

  • 開發中產品:標的別
  • 開發中產品:各給藥途徑
  • 開發中產品:各類型分子
  • 開發中產品:各作用機制

H. Lundbeck A/S - 最近的開發平台趨勢

H. Lundbeck A/S - 暫停的計劃

H. Lundbeck A/S - 中止的開發中產品

H. Lundbeck A/S - 財務報表

H. Lundbeck A/S - 所在地與子公司

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08001CDB

Summary

Global Markets Direct's, 'H. Lundbeck A/S - Product Pipeline Review - 2016', provides an overview of the H. Lundbeck A/S's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by H. Lundbeck A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of H. Lundbeck A/S
  • The report provides overview of H. Lundbeck A/S including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses H. Lundbeck A/S's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features H. Lundbeck A/S's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate H. Lundbeck A/S's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for H. Lundbeck A/S
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding H. Lundbeck A/S's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • H. Lundbeck A/S Snapshot
    • H. Lundbeck A/S Overview
    • Key Information
    • Key Facts
  • H. Lundbeck A/S - Research and Development Overview
    • Key Therapeutic Areas
  • H. Lundbeck A/S - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • H. Lundbeck A/S - Pipeline Products Glance
    • H. Lundbeck A/S - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • H. Lundbeck A/S - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • H. Lundbeck A/S - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • H. Lundbeck A/S - Drug Profiles
    • carbamazepine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • idalopirdine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LuAF-35700
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nalmefene
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vortioxetine hydrobromide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LuAF-11167
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LUAF-20513
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LUAF-64280
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AF-40431
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize nAChR Alpha-4 Beta-2 for Brain Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit LRRK-2 for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • H. Lundbeck A/S - Pipeline Analysis
    • H. Lundbeck A/S - Pipeline Products by Target
    • H. Lundbeck A/S - Pipeline Products by Route of Administration
    • H. Lundbeck A/S - Pipeline Products by Molecule Type
    • H. Lundbeck A/S - Pipeline Products by Mechanism of Action
  • H. Lundbeck A/S - Recent Pipeline Updates
  • H. Lundbeck A/S - Dormant Projects
  • H. Lundbeck A/S - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • gaboxadol
      • LuAA-47070
      • idalopirdine
      • Lu-02750
      • Lu-35138
      • Lu-AA24493
      • LuAA-37096
      • LuAA-38466
      • LuAA-39959
      • LuAA-44608
      • LuAE-04621
      • ORE-10002
      • siramesine
      • tedatioxetine hydrobromide
      • vortioxetine hydrobromide
      • zicronapine
  • H. Lundbeck A/S - Company Statement
  • H. Lundbeck A/S - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • H. Lundbeck A/S, Key Information
  • H. Lundbeck A/S, Key Facts
  • H. Lundbeck A/S - Pipeline by Indication, 2016
  • H. Lundbeck A/S - Pipeline by Stage of Development, 2016
  • H. Lundbeck A/S - Monotherapy Products in Pipeline, 2016
  • H. Lundbeck A/S - Partnered Products in Pipeline, 2016
  • H. Lundbeck A/S - Partnered Products/ Combination Treatment Modalities, 2016
  • H. Lundbeck A/S - Out-Licensed Products in Pipeline, 2016
  • H. Lundbeck A/S - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • H. Lundbeck A/S - Filing rejected/Withdrawn, 2016
  • H. Lundbeck A/S - Phase III, 2016
  • H. Lundbeck A/S - Phase II, 2016
  • H. Lundbeck A/S - Phase I, 2016
  • H. Lundbeck A/S - Preclinical, 2016
  • H. Lundbeck A/S - Discovery, 2016
  • H. Lundbeck A/S - Pipeline by Target, 2016
  • H. Lundbeck A/S - Pipeline by Route of Administration, 2016
  • H. Lundbeck A/S - Pipeline by Molecule Type, 2016
  • H. Lundbeck A/S - Pipeline Products by Mechanism of Action, 2016
  • H. Lundbeck A/S - Recent Pipeline Updates, 2016
  • H. Lundbeck A/S - Dormant Developmental Projects,2016
  • H. Lundbeck A/S - Discontinued Pipeline Products, 2016
  • H. Lundbeck A/S, Subsidiaries

List of Figures

  • H. Lundbeck A/S - Pipeline by Top 10 Indication, 2016
  • H. Lundbeck A/S - Pipeline by Stage of Development, 2016
  • H. Lundbeck A/S - Monotherapy Products in Pipeline, 2016
  • H. Lundbeck A/S - Partnered Products in Pipeline, 2016
  • H. Lundbeck A/S - Out-Licensed Products in Pipeline, 2016
  • H. Lundbeck A/S - Pipeline by Top 10 Target, 2016
  • H. Lundbeck A/S - Pipeline by Route of Administration, 2016
  • H. Lundbeck A/S - Pipeline by Molecule Type, 2016
  • H. Lundbeck A/S - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top